DVA - DaVita Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

DVA

DAVITA INC.

NYSE

$177.50

▼ DOWN 0.67% (-1.20)

KEY STATISTICS

Market Cap$11.47 B

52w High$247.49

52w Low$101.00

Dividend Yield—

Frequency—

P/E13.87

Volume52.53K

Shares Out.64.20M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Javier J. Rodriguez

COMPENSATION 2026

Salary$1,500,000

Stock Awards$11,442,481

Incentive Plan Pay$2,089,491

All Other Comp.$478,643

Total$18,210,597

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 31, 1995

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

78,000

PRICE TARGET

Target High$270.00

Target Low$215.00

Target Median$222.00

Target Consensus$235.67

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$3.52B

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2013-09-09	Forward	2:1
2004-06-16	Forward	3:2
1997-10-21	Forward	5:3

ETFS HOLDING THIS STOCK

ETFS HOLDING

474

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

88.53%

HOLDERS

1,034

TOP 8 OF 1,034 · RANKED BY POSITION SIZE

Berkshire Hathaway Inc

Blackrock Institutional Trust Company, N.A.

Blackrock Fund Advisors

PRICE

$177.50 ▼ DOWN 0.67% (−$1.20)

OVERLAYS

About DaVita Inc.

https://www.davita.com ↗

DaVita Inc. provides kidney dialysis, laboratory, and comprehensive kidney care services across outpatient, hospital, and home settings for over 243,000 patients in the U.S. and internationally.

INDUSTRY

Medical - Care Facilities

A SERVICE DAVITA INC. IS KNOWN FOR

Kidney Dialysis & Integrated Kidney Care (IKC)

DaVita is a leading provider of kidney dialysis services, specializing in in-center, peritoneal, and home dialysis, with a focus on an Integrated Kidney Care model for comprehensive chronic kidney disease management.

COMPETITORS

COMPETITOR

DaVita in 2025

SENTIMENT: − NEGATIVE

EARNINGS · FEBRUARY 2025

DaVita Stock Plummets After Disappointing 2025 Earnings Outlook

DaVita's stock experienced a sharp decline, dropping by as much as 11% in after-hours trading, after the company released a weaker-than-expected earnings per share guidance for 2025. While its fourth-quarter 2024 earnings surpassed analyst expectations, the cautious forecast for the upcoming year unsettled investors, sparking significant concern over rising costs and future profitability.

CAPITAL ALLOCATION · AUGUST 2025 · IN PROGRESS

DaVita Doubles Down on Share Buybacks with a $2.0 Billion Increase in Authorization Amidst Rising Debt Costs

In a significant capital allocation move, DaVita's Board of Directors authorized an additional $2.0 billion for its share repurchase program in August 2025. This decision underscores a continued commitment to returning capital to shareholders, even as the company navigates a landscape of rising interest expenses and operational challenges.